CompanyGraph
Makes protein-based medicines like EPOGEN and Neulasta inside FDA-approved biological manufacturing facilities tied to specific locations.
- Returns appear driven by leverage
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: grey zone
- Interpretations3 currently firing — 1 · 2
What this company is and how it runs — written from structure, not news.
Amgen makes protein medicines — EPOGEN for dialysis patients, Neulasta for chemotherapy patients, BLINCYTO for leukemia — by growing engineered Chinese hamster ovary cells in large bioreactors at three specific facilities in Thousand Oaks, Rhode Island, and Puerto Rico. Each FDA licence ties a particular cell line to a particular building, so the same scientists who optimize how a cell expresses its target protein work in the same facility where commercial batches run, giving Amgen a feedback loop between the lab and the production floor that a competitor using a third-party cell line supplier in a separate contract-manufacturing site cannot replicate. Because the finished protein degrades quickly, a cold chain begins immediately after production and runs unbroken to the clinic, which means every dose of a given medicine depends entirely on whichever one of those three named sites is licensed to make it — a contamination event or FDA shutdown order at any single site halts that medicine with no ready alternative, because moving the cell line to a new facility requires a full new regulatory approval cycle. A biosimilar competitor trying to break into this market faces a similar wall: proving their version behaves like Amgen's requires separate clinical trials costing over $100 million and at least eighteen months, for each product they want to challenge.
How does this company make money?
The company sells its biologics by the unit to hospitals, specialty pharmacies, and drug distributors. The price for each medicine is negotiated every year with pharmacy benefit managers and government payers. Medicines that doctors administer directly in a clinic — like EPOGEN — are reimbursed through Medicare Part B, meaning the government pays a set rate per dose given to a patient.
What makes this company hard to replace?
Any competitor that wants to sell a biosimilar version of one of these medicines cannot simply copy the formula — they must run separate FDA clinical trials proving their version behaves the same as the original. That process takes at least 18 months and costs more than $100 million per product. That cost and time requirement applies to every single medicine a competitor wants to challenge, making it very hard to displace any one product quickly.
What limits this company?
Each bioreactor suite has to pass its own separate FDA inspection before it can make a specific protein commercially. And a suite set up for one protein cannot simply be switched to make a different one — doing so would require a full new approval cycle because of contamination risk. That means the number of approved suites, not money, sets the hard ceiling on how many products can be made at any one time.
What does this company depend on?
The company cannot operate without: the Chinese hamster ovary cell lines that express each protein; FDA biologics license approvals tied to each named manufacturing facility; cold-chain logistics networks that keep products between 2 and 8°C from factory to patient; specialized bioreactor equipment from companies like Cytiva and Sartorius; and, for small molecule products like Otezla, active pharmaceutical ingredients sourced from contract manufacturers.
Who depends on this company?
Dialysis centers that give EPOGEN to kidney patients would face shortages of their main anemia treatment. Oncology practices that use Neulasta to protect chemotherapy patients from dangerous infections would lose that capability. Rheumatology clinics prescribing Enbrel for autoimmune conditions like rheumatoid arthritis would have to find alternative TNF inhibitor treatments for their patients.
How does this company scale?
Once a cell line is established and approved, adding more bioreactor suites running the same process produces predictable output at scale — the yield math is reliable. What does not scale easily is developing the cell lines in the first place. Engineering a mammalian cell to reliably express a specific protein requires deep proprietary expertise and cannot be handed off to an outside supplier, because the cell line is the core manufacturing asset the entire product is built around.
What external forces can significantly affect this company?
Medicare has specifically targeted reimbursement cuts at erythropoiesis-stimulating agents like EPOGEN and Aranesp, directly compressing what the company gets paid per dose. In Europe, biosimilar approval pathways have opened the door to cheaper competing versions of established protein medicines. China's push to build its own domestic biomanufacturing industry is reducing the company's access to what would otherwise be one of the largest pharmaceutical markets in the world.
Where is this company structurally vulnerable?
The FDA licence for each medicine names a specific facility. If the FDA shuts down one of the three sites — Thousand Oaks, Rhode Island, or Puerto Rico — after a contamination event or a failed inspection, every medicine approved at that site stops being made. There is no backup site ready to step in, because moving production to a different facility requires filing a new application and going through a full new inspection cycle that cannot be sped up past regulatory minimums.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
- Returns appear driven by leverage
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
High ROE Relative To Gross Margin
Three observations align: return on equity is high relative to gross margin, revenue has grown for three consecutive years, and the company has been profitable for five years. Together they describe strong equity returns in a stable, growing context.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.